全文获取类型
收费全文 | 624篇 |
免费 | 29篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 23篇 |
妇产科学 | 26篇 |
基础医学 | 51篇 |
口腔科学 | 54篇 |
临床医学 | 88篇 |
内科学 | 166篇 |
皮肤病学 | 10篇 |
神经病学 | 24篇 |
特种医学 | 24篇 |
外科学 | 76篇 |
综合类 | 6篇 |
一般理论 | 2篇 |
预防医学 | 40篇 |
眼科学 | 9篇 |
药学 | 24篇 |
中国医学 | 2篇 |
肿瘤学 | 28篇 |
出版年
2023年 | 3篇 |
2022年 | 3篇 |
2021年 | 8篇 |
2020年 | 7篇 |
2019年 | 11篇 |
2018年 | 14篇 |
2017年 | 11篇 |
2016年 | 9篇 |
2015年 | 12篇 |
2014年 | 21篇 |
2013年 | 11篇 |
2012年 | 24篇 |
2011年 | 47篇 |
2010年 | 35篇 |
2009年 | 21篇 |
2008年 | 36篇 |
2007年 | 30篇 |
2006年 | 36篇 |
2005年 | 37篇 |
2004年 | 40篇 |
2003年 | 39篇 |
2002年 | 36篇 |
2001年 | 23篇 |
2000年 | 15篇 |
1999年 | 15篇 |
1998年 | 8篇 |
1997年 | 3篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 5篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 6篇 |
1990年 | 7篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 9篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 6篇 |
1981年 | 2篇 |
1978年 | 7篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1971年 | 3篇 |
1968年 | 1篇 |
1966年 | 2篇 |
1965年 | 3篇 |
排序方式: 共有656条查询结果,搜索用时 835 毫秒
71.
Correlation of Quantitative Assay of HBsAg and HBV DNA Levels During Chronic HBV Treatment 总被引:3,自引:0,他引:3
Ozaras R Tabak F Tahan V Ozturk R Akin H Mert A Senturk H 《Digestive diseases and sciences》2008,53(11):2995-2998
Background and aim Viral load is used for the diagnosis and monitoring the treatment of chronic hepatitis B (CHB). These methods are molecular-based
and are expensive. Previous studies suggest that quantitative hepatitis B surface antigen (HBsAg) studied by automated chemiluminescent
microparticle immunoassay can be a surrogate marker. In this study, we aimed to investigate whether quantitative HBsAg correlates
hepatitis B virus (HBV) DNA levels during CHB treatment. Methods The study included 18 patients (13 male, 5 female, mean age: 33 ± 9 years) with CHB. They were given pegylated interferon ± lamivudine
for 52 months and serum samples were obtained in weeks 0, 4, 8, 24, 48, 52, and 76. HBV DNA was measured by TaqMan polymerase
chain reaction (PCR; Erasmus MC, University Medical Center, Rotterdam, The Netherlands). Quantitative HBsAg was studied by
automated chemiluminescent microparticle immunoassay (Architect HBsAg, Abbott, IL). Results HBV DNA levels were measured as follows: 9.66, 7.69, 7.06, 5.93, 5.89, 5.88, and 7.27 logarithmic genome equivalent/ml, respectively.
The corresponding HBsAg quantitation results were 42,888, 31,176, 37,882, 27,277, 28,279, 29,471, and 31,535 IU/ml, respectively.
They showed a significant correlation (canonical correlation = 0.85). Conclusions HBsAg studied by automated chemiluminescent microparticle immunoassay correlates with HBV DNA and can be a surrogate marker
during the monitoring of the efficacy of HBV treatment. 相似文献
72.
Senturk H Tahan V Canbakan B Dane F Ulger Y Ozaras R Tabak F Ozbay G 《Annals of hepatology》2008,7(1):52-58
There is controversial data in the literature about the characteristics or features of dual hepatitis B and C infection. Several studies have reported that the dual infection has a more severe histological picture; faster progression leading to cirrhosis and a higher risk for hepatocellular carcinoma compared with the single infections. These findings have not yet been supported. We assessed the patients with dual hepatitis B and C infection with respect to their different features in our country. METHOD: the chronic hepatitis patients of our clinics were tested, and both HBsAg and anti-HCV positive patients with chronic hepatitis were enrolled to the study. All patients were tested for the biochemical parameters and the presence of HBV-DNA and HCV-RNA. RESULTS: Of the 1950 patients, 51 (2.6%) were both HBsAg and anti-HCV positive and 67 were anti-delta positive. Patients were followed up for 5.4+/-2.1 years. Of the 51 dual hepatitis patients, 6 had no HBV-DNA and HCV-RNA detectable by PCR, 36 were only HCV-RNA positive, 9 were only HBV-DNA positive and 3 were both HBV-DNA and HCV-RNA positive. Dominant infection in (3/4) of the patients was hepatitis C. Clinical and histological properties of the cases with dual Hepatitis B and C infection showed no significant differences compared to the single infections. In conclusion, regarding the prognosis, no significant differences were found between such dual and single infections. Dual infection with hepatitis B virus and delta virus is a significantly more severe condition than the dual infection with hepatitis B and C viruses. 相似文献
73.
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon‐based therapy: FUNDAMENTAL,a Phase II trial
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
M. Buti R. Flisiak J.‐H. Kao W.‐L. Chuang A. Streinu‐Cercel F. Tabak P. Calistru T. Goeser J. Rasenack A. Horban G. L. Davis A. Alberti G. Mazzella S. Pol R. Orsenigo C. Brass 《Journal of viral hepatitis》2015,22(7):596-606
Alisporivir (ALV) is an oral, investigational host‐targeting agent, with pangenotypic activity against hepatitis C virus (HCV). This randomized, double‐blind, placebo‐controlled, Phase II study explored the efficacy and safety of ALV with peginterferon‐α2a/ribavirin (PR) in patients with chronic HCV genotype 1 infection in whom prior PR had failed (43% relapsers, 34% null responders and 23% partial responders). Four‐hundred‐and‐fifty‐nine patients were randomized (1:1:1:1) to ALV 600 mg once daily (QD), ALV 800 mg QD, ALV 400 twice daily (BID) or placebo plus PR for 48 weeks. When the global ALV trial programme was put on clinical hold, all patients in this study had received ≥31 weeks of randomized treatment; patients completed 48 weeks on PR alone. All ALV groups demonstrated superior rates of complete early virologic response (cEVR; primary endpoint) vs PR alone (P ≤ 0.0131), with highest cEVR rate seen with ALV 400 mg BID (74% vs 36% with PR alone; P < 0.0001). Respective SVR12 rates (key secondary endpoint) were 65% vs 26% in prior relapsers, 63% vs 5% in partial responders and 68% vs 3% in null responders. In patients who received >40 weeks of randomized treatment, the SVR12 rate was 89% for ALV 400 mg BID vs 30% for PR alone (P = 0.0053). Rates of viral breakthrough and relapse were lowest with ALV 400 mg BID. One case of pancreatitis (fully recovered) occurred with ALV/PR. Common AEs were headache, fatigue, anaemia, neutropenia and nausea. Hypertension was infrequent, but more common with ALV. ALV merits further investigation in interferon‐free regimens in combination with direct‐acting antiviral agents. 相似文献
74.
Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty‐four year Turkish experience in cladribine therapy
下载免费PDF全文
![点击此处可从《Hematological oncology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Sibel Hacioglu Yusuf Bilen Ali Eser Serdar Sivgin Emel Gurkan Rahsan Yildirim Ismet Aydogdu Mehmet Hilmi Dogu Mehmet Yilmaz Omur Kayikci Anil Tombak Irfan Kuku Harika Celebi Meltem Olga Akay Ramazan Esen Serdal Korkmaz Ali Keskin 《Hematological oncology》2015,33(4):192-198
In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty‐six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first‐line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy (95%) was again cladribine at second‐line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28‐month median OS was 91.7% in all patients and 25‐month median OS 96% for patients who were given cladribine as first‐line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
75.
76.
Tahan V Ozaras R Lacevic N Ozden E Yemisen M Ozdogan O Mert A Tabak F Avsar E Celikel CA Ozbay G Kalayci C Senturk H Tozun N 《Digestive diseases and sciences》2004,49(10):1575-1577
An increasing frequency of hepatic granulomas, up to 10%, in chronic hepatitis C patients is reported, and their presence is considered to be a predictor of treatment success. However, there is only one prevalence study on granuloma in chronic hepatitis B, and its significance for treatment outcome is unknown. We aimed to determine the prevalence of hepatic granulomas in a larger group of chronic hepatitis B patients and to compare their presence with the response to interferon therapy. Biopsy specimens of chronic hepatitis B patients were reevaluated for the presence of hepatic granulomas. All patients with hepatic granuloma were screened for other granulomatous diseases by tuberculin skin test, chest X-ray and computed tomography, venereal disease research laboratory, Brucella agglutination tests, and exposure to hepatotoxic agents. We screened 663 cases of chronic hepatitis B. Hepatic granulomas were found in 10 cases (1.5%). The granulomas could not be ascribed to any other reason. Of the 10 patients with hepatic granulomas, 4 responded to interferon therapy, 2 dropped out, and 4 were nonresponders. We conclude that hepatic granuloma is a rare finding in chronic hepatitis B and its presence does not seem to predict the response to interferon therapy. 相似文献
77.
Senturk H Ersoz G Ozaras R Kaymakoglu S Bozkaya H Akdogan M Mert A Bozdayi M Tabak F Yenice N Ozbay G 《Digestive diseases and sciences》2003,48(6):1124-1129
We aimed to compare the efficacy of interferon-2b (IFN) induction treatment in combination with ribavirin to IFN induction alone in chronic hepatitis C. In total, 125 patients (66 male, 59 female, mean age: 48 ± 9, range: 21–70) were enrolled and randomized into two arms: In the first, patients received 5 MU/day of IFN for 4 weeks followed by 3 MU/day for the next 4 weeks. Treatment was continued with 3 MU three times a week IFN for an additional 40 weeks. Ribavirin was administered 1000–1200 mg/day according to the body weight for the entire 48-week period. In the second arm, patients received placebo in addition to IFN. Fifty-nine patients were placed in the ribavirin arm and 66 in placebo arm. All patients were genotype 1. At week 48, 24/66 (36%) from the placebo and 31/59 (52%) from the ribavirin group responded (P < 0.05). However, during the 24-week untreated follow-up period, 13/24 (54%) from the placebo, and 8/31 (26%) from the ribavirin group relapsed (P = 0.002.), resulting in a sustained virologic response (SVR) rate of 17% in the placebo and 39% in the ribavirin group (P = 0.005.) In conclusion, IFN induction treatment in combination with ribavirin is superior to IFN induction treatment alone in genotype 1 patients, and the SVR rate of 39% is encouraging. 相似文献
78.
Fehmi Tabak Resat Ozaras Yusuf Erzin Aykut Ferhat Celik Gulsen Ozbay Hakan Senturk 《Liver international》2003,23(5):351-354
Abstract: Metronidazole and ornidazole, synthetic nitroimidazole derivatives, are used in the treatment of infections caused by anaerobic bacteria and protozoa. The drugs are well tolerated and serious side effects are very rarely encountered. Hepatotoxicity is a rare side effect and hitherto only six cases have been reported. We describe three patients who developed hepatitis after ornidazole use and review the previously reported cases. All three cases used ornidazole in conventional doses and developed hepatitis and associated cholestasis. They improved 1–2 months after discontinuation. We concluded that nitroimidazole derivatives may cause hepatotoxic damage resembling acute cholestatic hepatitis. Early recognition and withdrawal of the drug may prevent further damage. 相似文献
79.
In Switzerland preimplantation genetic diagnosis is limited by law to polar body biopsy (PBB). The indications for PBB include unexplained recurrent miscarriage and improvement of the outcome of in vitro fertilisation (IVF) cycles in women at an advanced reproductive age. In this article we report the first birth of a healthy child after polar body biopsy in Switzerland in a case of unexplained miscarriage after IVF. 相似文献
80.
Caglar?CuhadarogluEmail author Mustafa?Erelel Levent?Tabak Zeki?Kilicaslan 《BMC infectious diseases》2002,2(1):14